Nyxoah Partners with UAE's Sheikh Shakhbout Medical City to Expand OSA Therapy Access
Event summary
- Nyxoah signed an MoU with Sheikh Shakhbout Medical City (SSMC) to improve OSA therapy management in the Middle East.
- The partnership aims to establish SSMC as a regional training hub for Nyxoah's Genio hypoglossal nerve stimulation therapy.
- Collaboration includes potential clinical research on sleep apnea and chronic disease management.
- SSMC is a flagship hospital in the UAE and a subsidiary of PureHealth, the largest healthcare group in the Middle East.
The big picture
Nyxoah's strategic partnership with SSMC underscores its focus on expanding access to innovative OSA treatments in high-prevalence regions. The collaboration aligns with broader industry trends of regional healthcare hub development and the integration of advanced neuromodulation therapies into standard sleep apnea management. With the Middle East representing a significant market opportunity, this initiative could enhance Nyxoah's competitive positioning in the global OSA therapy landscape.
What we're watching
- Regional Expansion
- How Nyxoah's partnership with SSMC will accelerate Genio therapy adoption in the Middle East.
- Clinical Research
- Whether the collaboration will yield significant advancements in OSA and chronic disease management.
- Training Hub Impact
- The pace at which SSMC can establish itself as a leading regional training center for Genio therapy.
Related topics